Other substances

Folic acid

A glutamic acid derivative.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

1
 Supporting references
0
 Contradictory references
5
 AI-suggested references
2
 Clinical trials

General information

Folic acid on PubChem

 

Structure image - Folic acid

C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)NC(=N3)N

Supporting references

Link Tested on Impact factor Notes Publication date
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)
nsp13 Small molecule In silico 		in silico 5.16

Predicted to inhibit the SARS-CoV-2 nsp13 helicase (both wild type and with C17747T and A17858G mutations).

 Sep/24/2020

AI-suggested references

Link Publication date
Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019- nCoVMpro), Molecular Docking and SAR Study.
Apr/24/2020
Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein
Apr/13/2020
A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
Oct/29/2020
Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein
Oct/08/2021
In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19.
Jan/28/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04631536 Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC Active, not recruiting Phase 3 Jan/10/2021 Jul/01/2022
  • Alternative id - Lebanese American University
  • Interventions - Drug: Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - LAUMCRH, Beirut, Lebanon
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 42
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Improvement|Need for ICU admission or invasive mechanical ventilation|All cause mortality|Occurrence of side effects
NCT04354428 Treatment for COVID-19 in High-Risk Adult Outpatients Active, not recruiting Phase 2|Phase 3 Apr/16/2020 Jan/01/2021
  • Alternative id - STUDY00009878|INV-017062
  • Interventions - Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
Export (.csv)